The Senate Judiciary Committee today voted 16-5 to approve the Creating and Restoring Equal Access to Equivalent Samples Act (S. 974). The AHA-supported bill would allow generic drug manufacturers facing certain anticompetitive delay tactics to bring an action in federal court for injunctive relief. More than 45 organizations, including the AHA, last week urged the committee to support the legislation to “end the anticompetitive abuses utilized by some brand-name manufacturers, help restore the balance between innovation and affordability that Congress intended, and achieve the goal of more affordable prescription drugs.” The Congressional Budget Office estimates the legislation will save $3.8 billion over 10 years.

Related News Articles

Headline
Hospitals and health systems may apply through Feb. 19 for the 2019 AHA Equity of Care Award, which recognizes organizations participating in the AHA's #…
Headline
The American Board of Medical Specialties has released an updated guide to the specialty and subspecialty certifications offered by its 24 member boards.
Headline
The AHA and the Federation of American Hospitals today urged Congress to oppose any legislation that would repeal current law limiting self-referral to…
Headline
A coalition of 40 health care and public health organizations, including the AHA, today urged the Senate to quickly pass the Pandemic and All-Hazards…
Headline
Joseph Miller, vice president of behavioral health care transformation services at Hackensack (N.J.) Meridian Health, will serve as 2019 chair of the AHA's…
Perspective
We’re 11 days into 2019 … we’ve returned to a divided government …and the partial government shutdown continues.